Kenney Christopher John's Form 4 filing
Xenon Pharmaceuticals Inc. (XENE) · filed Aug 31, 2026
- Accession no.
- 0001193125-26-377309
- Filed
- Aug 31, 2026, 9:59 PM ET
- Trade date
- Aug 28, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $425.8K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kenney Christopher JohnCIK 0001880129 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 28, 2026 | Common Shares | SSaleDisposed | −6,368 | $60.17 | −$383,145.37 | 702 | Direct | |
| Aug 28, 2026 | Common Shares | SSaleDisposed | −700 | $60.98 | −$42,683.62 | 2 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.